- Home
- BRT vs PRQR Comparison
BRT vs PRQR Comparison
Compare BRT & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- PRQR
- Stock Information
- Founded
- BRT 1972
- PRQR 2012
- Country
- BRT United States
- PRQR Netherlands
- Employees
- BRT N/A
- PRQR N/A
- Industry
- BRT Real Estate Investment Trusts
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- BRT Real Estate
- PRQR Health Care
- Exchange
- BRT Nasdaq
- PRQR Nasdaq
- Market Cap
- BRT 288.5M
- PRQR 232.8M
- IPO Year
- BRT N/A
- PRQR 2014
- Fundamental
- Price
- BRT $16.47
- PRQR $2.19
- Analyst Decision
- BRT Strong Buy
- PRQR Strong Buy
- Analyst Count
- BRT 1
- PRQR 8
- Target Price
- BRT $21.00
- PRQR $8.88
- AVG Volume (30 Days)
- BRT 25.0K
- PRQR 358.1K
- Earning Date
- BRT 11-06-2025
- PRQR 11-06-2025
- Dividend Yield
- BRT 6.06%
- PRQR N/A
- EPS Growth
- BRT N/A
- PRQR N/A
- EPS
- BRT N/A
- PRQR N/A
- Revenue
- BRT $98,407,000.00
- PRQR $20,129,184.00
- Revenue This Year
- BRT N/A
- PRQR N/A
- Revenue Next Year
- BRT $4.51
- PRQR N/A
- P/E Ratio
- BRT N/A
- PRQR N/A
- Revenue Growth
- BRT 2.46
- PRQR 8.65
- 52 Week Low
- BRT $14.17
- PRQR $1.07
- 52 Week High
- BRT $20.22
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- BRT 62.89
- PRQR 50.46
- Support Level
- BRT $16.01
- PRQR $1.91
- Resistance Level
- BRT $16.69
- PRQR $2.50
- Average True Range (ATR)
- BRT 0.42
- PRQR 0.16
- MACD
- BRT 0.05
- PRQR -0.03
- Stochastic Oscillator
- BRT 82.95
- PRQR 47.46
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.